Skip to main content
. Author manuscript; available in PMC: 2018 Dec 9.
Published in final edited form as: Leukemia. 2018 Jun 8;33(1):52–63. doi: 10.1038/s41375-018-0174-1

Figure 5. DHE suppresses viability of cytogenetically distinct AML cell lines and primary AML samples but not normal CD34+ cells.

Figure 5

(A) HL-60, OCI-AML3, MV4-11, MOLM13, MOLM14 and NB4 cells counts at indicated doses of DHE. (B) CFUs 7 days after treatment of MV4-11 or MOLM14 cells and 10–14 days after treatment of primary AMLs or normal CD34+ cells with vehicle or 10uM DHE. *p<0.05, **p<0.01, ***p<0.001 compared to vehicle.